The Rogosin Institute

The Rogosin Institute's early work in Lipid Control Disorders 

Rogosin’s work in lipid control began in the early 1980s when we collaborated with The Rockefeller University to pioneer clinical research of LDL-apheresis. LDL apheresis is a procedure that takes blood outside the body to remove the LDL-cholesterol, the major cholesterol carrying lipoprotein in your blood, and then returns the plasma and blood back to the body.

This treatment is a life prolonging procedure that is used to treat adults and children with genetically determined hypercholesterolemia that is resistant to of diet, medication and exercise. 

Rogosin’s clinical work contributed to the 1996 FDA approval of the LDL-apheresis procedure developed by Kaneka America Corp. 



The Maurice R. Greenberg Comprehensive Lipid Control Center (CLCC) became the first LDL-apheresis unit in the United States.

In addition to LDL-apheresis, the CLCC provides a full range of diagnostic and treatment services for adults and children with cholesterol and triglyceride disorders. These conditions can lead to narrowing of the arteries (atherosclerosis) that increases the chance of having a heart attack or stroke or cause pancreatitis. 

Our Continued Goals

Our staff of physicians, delete - nurse practitioners, dietitians and research scientists has expertise in lipid disorders and heart disease in adults and children. The goal of the programs at the CLCC is to reduce or eliminate risk factors that increase the likelihood of atherosclerosis.  This will prevent, halt progression of and reverse heart and blood vessel disease and other medical problems associated with lipid abnormalities.